Product Description
Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet endothelial growth factor receptor-alpha, and -beta, and the stem-cell factor receptor c-kit (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29684209/)
Mechanisms of Action: VEGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Renal Cell Carcinoma | Sarcoma | Oncology Unspecified
Known Adverse Events: Hypertension | Dysgeusia | Headache | Pain Unspecified | Hypopigmentation | Musculoskeletal Pain | Oncology Unspecified | Dyspnea | Anorexia | Diarrhea
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: BeiGene
Clinical Description
Countries in Clinic: Australia, China, France, Italy, Korea, Poland, Spain, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Renal Cell Carcinoma
Phase 2: Hypoxia|Kidney Diseases|Melanoma|Oncology Solid Tumor Unspecified|Sarcoma|Soft Tissue Cancer|Vascular Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MatchMel | P2 |
Recruiting |
Melanoma |
2027-07-01 |
|
| SPARTO | P2 |
Recruiting |
Soft Tissue Cancer|Renal Cell Carcinoma|Sarcoma|Kidney Diseases|Hypoxia|Vascular Cancer |
2026-11-17 |
|
| AMPHISARC | P2 |
Recruiting |
Sarcoma |
2026-01-01 |
57% |
| AMPHISARC | P2 |
Recruiting |
Sarcoma |
2026-01-01 |
57% |
| RENAVIV | P3 |
Recruiting |
Renal Cell Carcinoma |
2024-12-30 |
35% |